COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
The lack of effective PTSD treatments is “a crisis,” according to the PTSD Psychopharmacology Working Group. About one in 20 people in the UK suffer from PTSD, and current treatment options are ineffective for 40% of these patients.
COMPASS Pathways (CMPS) is launching a phase II trial to see if its psilocybin therapy model for treatment-resistant depression, COMP360, can also bring relief to patients with PTSD.
The trial will assess 20 patients who experienced trauma as adults, who will be given a single dose of the psilocybin formulation followed by 12 weeks of therapy protocols.
Researchers will measure the safety of the drug as will as improvements in PTSD symptoms, functionality, and quality of life.